For research use only. Not for therapeutic Use.
DM1-SMe（Cat No.:I005978）is a derivative of the antitumor agent DM1, which is known for its ability to inhibit microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. The S-methylation in DM1-SMe enhances its solubility and bioavailability, potentially improving its therapeutic efficacy. This compound is primarily investigated for its applications in targeted cancer therapies, particularly in combination with antibody-drug conjugates. Preclinical studies suggest that DM1-SMe may exhibit potent antitumor activity against various malignancies, making it a promising candidate for further research and clinical development in oncology.
| Catalog Number | I005978 |
| CAS Number | 138148-68-2 |
| Synonyms | DM1-SMe; DM1-SSMe; maytansinoid derivative with ADC linker. Maytansine or mertansine or emtansine derivative; N2/’-deacetyl-N2/’-[3-(methyldithio)-1-oxopropyl]maytansine.;(14S,16S,33S,2R,4R,10E,12Z,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10- |
| Molecular Formula | C36H50ClN3O10S2 |
| Purity | ≥95% |
| Target | microtubular inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| IUPAC Name | [(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl-[3-(methyldisulfanyl)propanoyl]amino]propanoate |
| InChI | InChI=1S/C36H50ClN3O10S2/c1-20-11-10-12-27(47-8)36(45)19-26(48-34(44)38-36)21(2)32-35(4,50-32)28(49-33(43)22(3)39(5)29(41)13-14-52-51-9)18-30(42)40(6)24-16-23(15-20)17-25(46-7)31(24)37/h10-12,16-17,21-22,26-28,32,45H,13-15,18-19H2,1-9H3,(H,38,44)/b12-10-,20-11-/t21-,22+,26+,27-,28+,32+,35+,36+/m1/s1 |
| InChIKey | ZLUUPZXOPGORNG-UDXCHANISA-N |
| SMILES | C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C\C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCSSC)C)\C)OC)(NC(=O)O2)O |
| Reference | </br>1:Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24. PubMed PMID: 23798344; PubMed Central PMCID: PMC4260400. |
